RSV is one of the most common causes of lower respiratory tract infection in infants and young children. Although infection often produces cold-like symptoms, the virus can spread into the small airways and lungs, causing bronchiolitis or pneumonia. Infants, particularly those born prematurely or with underlying medical conditions, are at increased risk of respiratory distress, dehydration, and hospitalization. Because the virus circulates seasonally and can infect children repeatedly throughout life, reducing the severity of a first infection is a major public health objective.

Nirsevimab works by providing passive immunity rather than stimulating the infant’s immune system to produce its own antibodies. The drug is a laboratory-engineered antibody that binds to the fusion protein on the surface of RSV. This protein is essential for the virus to enter human cells and spread between them. By attaching to a vulnerable region of the fusion protein, nirsevimab can neutralize RSV particles before they establish infection or limit the progression of infection after exposure. Its extended duration of action allows a single administration to provide protection throughout much of an RSV season.

The study evaluated outcomes during two consecutive RSV seasons and compared hospitalization patterns among children who received nirsevimab with those who did not. Its principal focus was hospitalization associated with RSV lower respiratory tract infection, a clinically important endpoint because it reflects severe disease rather than infection detected only through outpatient testing. The investigators also examined whether nirsevimab was associated with changes in hospitalizations from non-RSV infections and asthma, conditions that could help indicate whether the observed effect was specifically linked to RSV prevention.

Across the 2023–2024 and 2024–2025 seasons, children who received nirsevimab experienced substantially fewer hospitalizations related to RSV lower respiratory tract infections during the first year of follow-up. The consistency of the association across both seasons is notable because the timing and intensity of RSV circulation can vary from year to year. Seasonal differences in viral transmission, population immunity, healthcare-seeking behavior, and the prevalence of other respiratory pathogens can all influence hospitalization rates. Observing a similar protective pattern in two successive seasons strengthens the evidence that the reduction was related to nirsevimab rather than to a single unusual epidemic.

The researchers did not find evidence that nirsevimab reduced hospitalizations caused by non-RSV infections. This distinction is biologically important. Nirsevimab targets RSV specifically and does not function as a broad antiviral or general immune stimulant. A selective reduction in RSV-related admissions, without a comparable decline in hospitalizations from unrelated infections, supports the interpretation that the treatment’s benefit is pathogen-specific. It also suggests that the results were not simply the consequence of broader differences in healthcare access, general illness prevention, or the likelihood that treated children were hospitalized.

The analysis also found no association between nirsevimab and reduced asthma-related hospitalizations. Asthma is influenced by multiple factors, including genetic susceptibility, airway inflammation, environmental exposures, and viral triggers. Severe RSV infection early in life has been linked in some research with later respiratory problems, but a potential long-term relationship cannot be established by observing short-term hospitalization patterns alone. The absence of a detected reduction in asthma admissions indicates that the immediate preventive effect of nirsevimab should not be interpreted as evidence that the antibody prevents asthma or modifies all forms of respiratory disease.

The apparent benefit was limited to the first year of follow-up. During the second year, the study did not identify a corresponding reduction in RSV-related hospitalizations. Several explanations are possible. The antibody’s protection is designed to last through a defined period rather than indefinitely, and children may encounter RSV after the period of effective antibody coverage has ended. In addition, older children generally face a different risk profile than infants, with more mature airways and immune systems reducing the likelihood of severe disease. Changes in exposure, vaccination or prophylaxis practices, and the underlying circulation of RSV may also contribute to differences between the first and second years.

Because the study was observational, the findings demonstrate an association rather than definitive proof of causation. Treatment decisions, underlying health, birth history, healthcare access, and other characteristics may differ between children who receive nirsevimab and those who do not. Researchers use statistical methods to account for measurable differences, but unmeasured factors can remain. Even so, the results complement clinical trial evidence by showing how nirsevimab performed under routine conditions and across more than one RSV season. The findings suggest that targeted antibody protection can meaningfully reduce severe RSV disease in infants during the period when they are most vulnerable, while underscoring that it does not prevent unrelated infections or guarantee protection beyond the first year.

Subject of Research: Nirsevimab and its association with RSV lower respiratory tract infection hospitalizations in children.

Web References: https://doi.org/10.1001/jamapediatrics.2026.3384

References: Gabet A, et al. Study published in JAMA Pediatrics. DOI: 10.1001/jamapediatrics.2026.3384.

Keywords: Nirsevimab, respiratory syncytial virus, RSV, lower respiratory tract infection, bronchiolitis, infant hospitalization, monoclonal antibody, passive immunity, asthma, pediatric infectious disease, viral prevention, immunization

RSV is a ubiquitous pathogen responsible for significant morbidity and mortality in infants and young children worldwide. It primarily targets the lower respiratory tract, causing ailments such as bronchiolitis and pneumonia. Particularly vulnerable are neonates and infants under six months, in whom RSV infection often necessitates hospital admission and supportive care. Moreover, beyond acute illness, early RSV infection is implicated in long-term pulmonary sequelae including chronic wheezing, asthma development, and recurring respiratory hospitalizations, thereby exerting a lasting burden on child health.

The UK’s national maternal RSV vaccination program, launched on September 1, 2024, offers the bivalent Prefusion F vaccine to pregnant women from 28 weeks’ gestation. The vaccine elicits robust maternal antibody responses targeting both RSV A and B subtypes by focusing on the prefusion conformation of the RSV F protein—an antigenic structure known to induce potent neutralizing immunity. Passive transplacental transfer of these antibodies confers direct protection to the infant, filling a critical gap as vaccines for newborns themselves remain elusive due to their immature immune systems.

To rigorously assess this program’s effectiveness, researchers analyzed data from 289,399 infants born between September 2, 2024 and March 24, 2025, covering approximately 90% of births in England during that interval. By linking national NHS maternity records, immunization registries, hospital admission data, and laboratory test results, this comprehensive cohort enabled precise estimation of vaccine impact on RSV-associated hospitalizations. Within this population, 4,594 cases of RSV-related hospitalization were documented, providing robust statistical power for vaccine efficacy analysis.

Comparative evaluation revealed striking disparities based on maternal vaccination status. Infants born to unvaccinated mothers, constituting 55% of the cohort, accounted for an overwhelming 87.2% of RSV hospital admissions. Conversely, those whose mothers received vaccination at least 14 days prior to delivery exhibited substantially lower hospitalization rates, reflecting a vaccine effectiveness exceeding 80%. This dramatic protective effect validates maternal immunization as a critical intervention to shield the most vulnerable infants during their initial months of life.

Timing emerged as a pivotal factor influencing the degree of neonatal protection conveyed. The study demonstrated a direct correlation between the interval from vaccination to delivery and vaccine effectiveness. When maternal immunization occurred at least four weeks before birth, effectiveness approached an impressive 85%, highlighting the importance of early administration within the recommended gestational window. This aligns with the biological premise that adequate time is necessary for optimal antibody titers to develop in the mother and be efficiently transferred across the placenta.

Interestingly, while full protection required a minimum of two weeks for maturation of the maternal immune response, even infants delivered 10 to 13 days post-vaccination benefitted from about a 50% reduction in hospital admissions compared with their unprotected counterparts. No significant risk reduction was noted if vaccination occurred less than ten days before birth. These nuanced findings emphasize that while early third-trimester vaccination remains optimal, some degree of neonatal immunity can be conferred even when administration occurs later in gestation, informing clinical decision-making in real-world settings.

Of particular note, the study also evaluated vaccine performance in preterm infants, a subgroup notoriously susceptible to severe RSV manifestations due to immature lungs and immune defenses. When the interval between vaccination and birth was maintained at a minimum of 14 days, vaccine effectiveness in preterm neonates reached nearly 70%. This is a promising advance given the high RSV-associated morbidity and mortality burden in preterm populations, supporting current global recommendations by the World Health Organization to vaccinate pregnant women early in the third trimester for maximal protective benefit.

Lead epidemiologist Matt Wilson remarked on the significance of these results, underscoring the robust nature of this large-scale real-world evidence which definitively demonstrates maternal RSV vaccination’s role in mitigating infant hospitalization risk. He highlighted ongoing efforts to analyze population-wide impact and durability of vaccine-derived protection extending beyond the neonatal period, including integration with monoclonal antibody prophylaxis in very preterm infants, to further refine pediatric RSV prevention strategies.

From a global health perspective, these findings have far-reaching implications. RSV remains a leading cause of infant mortality especially in low- and middle-income countries where access to intensive supportive care is limited. Wider implementation of maternal RSV vaccination programs could substantially decrease RSV-related infant deaths and hospital burdens in resource-constrained settings, representing a pivotal advancement in reducing worldwide child mortality and promoting respiratory health equity.

Technically, the bivalent Prefusion F vaccine utilizes stabilized prefusion conformations of the RSV fusion glycoprotein, eliciting high-affinity neutralizing antibodies that block viral entry into epithelial cells. Passive immunity transferred transplacentally protects infants by neutralizing RSV upon exposure, preventing viral replication and subsequent inflammatory lung injury. This mechanism circumvents the challenges of directly vaccinating neonates with immature adaptive immunity, positioning maternal immunization as a vital preventative measure.

The UKHSA study sets a new benchmark for vaccine effectiveness assessments using integrated national healthcare databases and real-world data analytics, establishing a framework for evaluating maternal immunizations against other neonatal pathogens. It further exemplifies the synergy of robust epidemiologic surveillance, innovative vaccine technology, and targeted public health interventions in safeguarding infant health with lasting population health benefits globally.

In conclusion, maternal vaccination against RSV represents a transformative intervention to dramatically reduce severe RSV disease and hospitalizations in young infants. The robust 81.3% vaccine effectiveness evidenced in this large national cohort underscores the critical importance of timely immunization during pregnancy to confer optimal passive protection. This study’s insights will guide clinical guidelines, inform public health policy, and catalyze broader global adoption of maternal RSV vaccines, offering newfound hope in the fight against a longstanding cause of infant respiratory morbidity and mortality.

Subject of Research: Maternal immunization for prevention of respiratory syncytial virus (RSV) infection in infants

Article Title: Maternal RSV Vaccination Dramatically Reduces Infant Hospitalization Risk: UKHSA’s Largest Real-World Study

News Publication Date: Saturday, 18 April 2026

Web References:

• www.escmid.org
• https://www.who.int/news-room/fact-sheets/detail/respiratory-syncytial-virus-(rsv)

References:

1. Wilson, M., Whitaker, H., Walker, J., et al. (2026). Maternal RSV vaccination and reduced risk of hospitalisation for babies in England – 2024/45. Oral presentation. ESCMID Global 2026.
2. Munro, A. P. S., Martinón-Torres, F., Drysdale, S.B. et al. (2023). The disease burden of respiratory syncytial virus in Infants. Current Opinion in Infectious Diseases. 36(5):379-384.
3. European Lung Foundation (ELF). (n.d.). Acute lower respiratory infections.
4. World Health Organization. (n.d.). Global Influenza Programme: Respiratory Syncytial Virus Surveillance.
5. World Health Organization. (2025). WHO outlines recommendations to protect infants against RSV – respiratory syncytial virus.
6. World Health Organization. (2025). Respiratory syncytial virus (RSV). https://www.who.int/news-room/fact-sheets/detail/respiratory-syncytial-virus-(rsv)

Keywords:
Respiratory syncytial virus, RSV, maternal vaccination, infant hospitalisation, lower respiratory tract infections, bivalent Prefusion F vaccine, passive immunity, preterm infants, epidemiology, vaccine effectiveness, neonatal protection, public health